May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Microperimetric Evaluation of Myopic Choroidal Neovascularization Treated With Intravitreal Bevacizumab (Avastin)
Author Affiliations & Notes
  • A. Scupola
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • M. C. Savastano
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • P. Sasso
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • B. Falsini
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • A. M. Minnella
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • D. Marangoni
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • A. Mastrocola
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • G. Zinzanella
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • S. Petroni
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • E. Balestrazzi
    Ophthalmology, Catholic University of Rome, Rome, Italy
  • Footnotes
    Commercial Relationships  A. Scupola, None; M.C. Savastano, None; P. Sasso, None; B. Falsini, None; A.M. Minnella, None; D. Marangoni, None; A. Mastrocola, None; G. Zinzanella, None; S. Petroni, None; E. Balestrazzi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2679. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Scupola, M. C. Savastano, P. Sasso, B. Falsini, A. M. Minnella, D. Marangoni, A. Mastrocola, G. Zinzanella, S. Petroni, E. Balestrazzi; Microperimetric Evaluation of Myopic Choroidal Neovascularization Treated With Intravitreal Bevacizumab (Avastin). Invest. Ophthalmol. Vis. Sci. 2008;49(13):2679. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effects of intravitreal bevacizumab (IB) in subfoveal choroidal neovascularization secondary to pathological myopia (mCNV) by microperimetry analysis

Methods: : Ten eyes of 10 patients with mCNV were treated with 1.25 mg IB and evaluated over six months by visual acuity (VA), fundus related perimetry (MP1), optical coherence tomography (OCT), and fluorescein angiography (FA). Five (50%) eyes were treated with a single injection and five (50%) eyes received two injections. Main outcome measures were microperimetry shift of preferred retinal locus (PRL) and macular sensitivity (MS).

Results: : In all study eyes, post-injection microperimetric exam revealed a PRL shift towards anatomic fovea. Mean PRL location at baseline was 2.25 degrees (standard error, SE=0.49) from the fovea, with a mean distance reduction of 0.79 degrees (p<0.0001) at 6 months post-injection. Mean sensitivity at baseline was 5.72 dB (SE=0.95) with a mean increase of 2.72 dB (p<0.0001) at 6 months post-injection. The amount of post-injection PRL shift was quantitatively correlated (p < 0.01) with the reduction of foveal thickness.

Conclusions: : Results of this pilot trial show significant changes in PRL and MS following IB for mCNV, in agreement with VA, OCT and Fluorescein angiography improvements.

Keywords: choroid: neovascularization • myopia • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×